4D Molecular Therapeutics, Inc.FDMTNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank75
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-187.24%
↑ 100% vs avg
Percentile
P75
Within normal range
Streak
1 yr
Consecutive growthExpanding
Average
-55043.56%
Historical baseline
PeriodValueYoY Change
2025-187.24%+100.0%
2024-489556.76%-93262.8%
2023-524.36%+84.8%
2022-3439.73%-788.8%
2021-387.02%+4.6%
2020-405.68%+36.5%
2019-638.75%-830.3%
2018-68.66%+62.7%
2017-183.87%-